Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Medtronic
Boehringer Ingelheim
Merck
Johnson and Johnson

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Travoprost - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for travoprost and what is the scope of patent protection?

Travoprost is the generic ingredient in four branded drugs marketed by Novartis, Alcon Pharms Ltd, Apotex Inc, Mylan, and Par Pharm, and is included in six NDAs. There are seven patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Travoprost has seventy-eight patent family members in twenty-four countries.

There are fifteen drug master file entries for travoprost. One supplier is listed for this compound. There is one tentative approval for this compound.

Drug Sales Revenue Trends for travoprost

See drug sales revenues for travoprost

Recent Clinical Trials for travoprost

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Laboratorios Sophia S.A de C.V.Phase 1
Glaukos CorporationPhase 3
Novartis PharmaceuticalsPhase 4

See all travoprost clinical trials

Recent Litigation for travoprost

Identify potential future generic entrants

District Court Litigation
Case NameDate
Alcon Research, Ltd. v. Watson Laboratories, Inc.2016-04-07
Allergan, Inc. v. Sandoz, Inc.2015-10-19
Alcon Research Ltd. v. Micro Labs Limited2014-01-09

See all travoprost litigation

PTAB Litigation
PetitionerDate
Argentum Pharmaceuticals LLC2017-03-10
Apotex Corp.2013-07-05

See all travoprost litigation

Generic filers with tentative approvals for TRAVOPROST
Applicant Application No. Strength Dosage Form
  Start Trial  Start Trial0.004%SOLUTION; OPHTHALMIC

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for travoprost
Medical Subject Heading (MeSH) Categories for travoprost
Synonyms for travoprost
(((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(+)-Fluprostenol isopropyl ester
(1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-5-heptenoic acid 1-methyethyl ester
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate
(Z)-isopropyl 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl) phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
(Z)-isopropyl 7-((1R,2R)-3,5-dihydroxy-2-((S,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
157283-68-6
207742-69-6
283T686
5-Heptenoic acid, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl ester, (5Z)-
5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-
5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z)
AB2000145
AC-6103
AC1NQZOS
AKOS024458039
AL-6221
AL6221
AM84515
AN-10392
C26H35F3O6
CHEBI:746859
CHEMBL1200799
CS-2773
D01964
DB00287
EX-A1772
Fluprostenol isopropyl ester
Fluprostenol isopropyl ester, >=98%, ethanol solution
GTPL7102
HY-B0584
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R,E)-3-hydroxy-4-(3-(trifluoromethyl)-phenoxy)-but-1-enyl)-cyclopentyl)-hept-5-enoate
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
Izba
J-502633
LS-173521
M978
MKPLKVHSHYCHOC-AHTXBMBWSA-N
MolPort-006-167-507
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoate
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
RP17770
SC-50922
SCHEMBL93818
SR-01000942266
SR-01000942266-1
SR-01000946860
SR-01000946860-1
Travaprost
Travatan
Travatan (TN)
Travatan Alcon
Travatan Z
Travatanz
Travoprost (JAN/USAN/INN)
Travoprost [USAN:USP:INN:BAN]
Travoprost [USAN]
travoprostum
UNII-WJ68R08KX9
WJ68R08KX9
Z6131
ZINC4474682
Paragraph IV (Patent) Challenges for TRAVOPROST
Tradename Dosage Ingredient NDA Submissiondate
IZBA SOLUTION/DROPS;OPHTHALMIC travoprost 204822 2015-12-30
TRAVATAN Z SOLUTION/DROPS;OPHTHALMIC travoprost 021994 2009-02-19
TRAVATAN SOLUTION/DROPS;OPHTHALMIC travoprost 021257 2008-11-28

US Patents and Regulatory Information for travoprost

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis IZBA travoprost SOLUTION/DROPS;OPHTHALMIC 204822-001 May 15, 2014 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Novartis IZBA travoprost SOLUTION/DROPS;OPHTHALMIC 204822-001 May 15, 2014 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Par Pharm TRAVOPROST travoprost SOLUTION/DROPS;OPHTHALMIC 091340-001 Mar 1, 2013 RX No Yes   Start Trial   Start Trial   Start Trial
Novartis TRAVATAN Z travoprost SOLUTION/DROPS;OPHTHALMIC 021994-001 Sep 21, 2006 AT RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for travoprost

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alcon Pharms Ltd TRAVATAN travoprost SOLUTION/DROPS;OPHTHALMIC 021257-001 Mar 16, 2001   Start Trial   Start Trial
Alcon Pharms Ltd TRAVATAN travoprost SOLUTION/DROPS;OPHTHALMIC 021257-001 Mar 16, 2001   Start Trial   Start Trial
Novartis TRAVATAN Z travoprost SOLUTION/DROPS;OPHTHALMIC 021994-001 Sep 21, 2006   Start Trial   Start Trial
Novartis TRAVATAN Z travoprost SOLUTION/DROPS;OPHTHALMIC 021994-001 Sep 21, 2006   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for travoprost

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1920764 PA2012017 Lithuania   Start Trial PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
1514548 CA 2014 00038 Denmark   Start Trial PRODUCT NAME: TRAVOPROST; REG. NO/DATE: EU/1/01/199/001-002 20011127
1920764 C300540 Netherlands   Start Trial PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001-002 20011127
1920764 1290027-0 Sweden   Start Trial PRODUCT NAME: TRAVOPROST
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Mallinckrodt
Colorcon
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.